keyword
https://read.qxmd.com/read/34325247/development-and-validation-of-uplc-ms-ms-method-for-the-simultaneous-quantification-of-anaplastic-lymphoma-kinase-inhibitors-alectinib-ceritinib-and-crizotinib-in-wistar-rat-plasma-with-application-to-bromelain-induced-pharmacokinetic-interaction
#1
Hadir M Maher, Aliyah Almomen, Nourah Z Alzoman, Shereen M Shehata, Ashwaq A Alanazi
Bromelain, the aqueous extract of pineapple, has been used as a food supplement with reported nutritional and therapeutic benefits. Bromelain has anti-cancer, anti-inflammatory, antithrombotic, and fibrinolytic effects. Anaplastic lymphoma kinase (ALK) inhibitors, including alectinib (ALC), ceritinib (CER), and crizotinib (CRZ), have been efficiently used in the management of non-small cell lung cancer (NSCLC). The solubility of ALC, CER, and CRZ is much higher at low acidic pH (pH 1) and it decreases as the pH increases affecting their absorption with a subsequent decrease in their bioavailability...
July 22, 2021: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/34325189/incidence-of-suicide-mortality-among-childhood-cancer-survivors-a-population-based-retrospective-study
#2
Xue-Lei Fu, Hua Wu, Yan Qian, Xiao-Hong Jin, Hai-Rong Yu, Lin Du, Hong-Lin Chen, Ya-Qin Shi
The aim of our study was to investigate the suicide rates among childhood cancer survivors and assess factors associated with higher suicide risk. A review of data from Surveillance, Epidemiology, and End Results (SEER) program from 1975 to 2016 was performed for this study. This program is based on the US population and is supported by the US National Cancer Institute (NCI). Survivors diagnosed with childhood cancer were recorded. There were 40 suicides among 567,233 person-years, giving a suicide rate of 7...
July 18, 2021: Psychiatry Research
https://read.qxmd.com/read/34324949/outcomes-of-cardiac-diffuse-large-b-cell-lymphoma-dlbcl-in-the-rituximab-era
#3
Taha Al-Juhaishi, Sadeer G Al-Kindi
Background Cardiac diffuse large B-cell lymphoma (cDLBCL) are extremely rare. Introduction of rituximab has significantly improved survival in non-cardiac DLBCL, but there is limited data regarding outcomes of cDLBC. We sought to evaluate the outcomes of cDLBCL in both pre- and rituximab eras. Methods We identified all cDLBCL cases in the Surveillance, Epidemiology and End Results (SEER) registry from 1975 to 2016. We compared survival (overall and lymphoma-specific) of patients diagnosed prior to vs after Rituximab approval (2006)...
July 26, 2021: International Journal of Cardiology
https://read.qxmd.com/read/34324792/dramatic-response-to-alectinib-in-a-patient-with-alk-rearranged-squamous-cell-lung-cancer
#4
Jun Shiihara, Fumiyoshi Ohyanagi, Hikari Amari, Minemichi Toda, Hiroki Tahara, Motoi Yuzawa, Yuki Maeda, Motoko Nomura, Yoshiko Mizushina, Yoshiaki Nagai, Hiromitsu Ohta, Yasuhiro Yamaguchi
Lung cancers with anaplastic lymphoma kinase (ALK) rearrangements are highly sensitive to treatment with ALK tyrosine kinase inhibitors (TKIs). Due to the very low rate of patients with squamous cell carcinoma enrolled in clinical trials, the efficacy of ALK inhibitors in patients with ALK-rearranged squamous cell carcinoma in the lung remains unclear. Herein, we present the case of a 70-year-old female patient with squamous cell lung cancer harboring the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene...
July 29, 2021: Thoracic Cancer
https://read.qxmd.com/read/34324764/acute-lymphoblastic-leukemia-in-infants-a-quarter-century-of-nationwide-efforts-in-japan
#5
REVIEW
Daisuke Tomizawa, Takako Miyamura, Katsuyoshi Koh, Eiichi Ishii
Acute lymphoblastic leukemia (ALL) with KMT2A gene rearrangement (KMT2A-r) in infants is a biologically and clinically unique disease and one of the most difficult-to-cure forms of pediatric leukemia. Continuing nationwide efforts by conducting multicenter clinical trials have been carried out in Japan since the mid-1990s by introducing allogeneic hematopoietic stem cell transplantation (HSCT) in first remission, which led to a modest improvement in outcome of infants with KMT2A-r ALL. Because of the emerging evidence that HSCT does not benefit every infant with KMT2A-r ALL, the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) trial MLL-10 introduced risk stratification using age and presence of CNS leukemia and introduced intensive chemotherapy including high-dose cytarabine in early consolidation; indication of HSCT was restricted to the patients with high-risk features...
July 29, 2021: Pediatrics International: Official Journal of the Japan Pediatric Society
https://read.qxmd.com/read/34324707/cancer-patterns-in-nasopharyngeal-carcinoma-multiplex-families-over-15-years
#6
Kelly J Yu, Wan-Lun Hsu, Chun-Ju Chiang, Tseng-Cheng Chen, Zhiwei Liu, Pei-Jen Lou, Scott Diehl, Alisa M Goldstein, Chien-Jen Chen, Cheng-Ping Wang, Allan Hildesheim
BACKGROUND: Genetic and environmental factors are important determinants of nasopharyngeal carcinoma (NPC). NPC is associated with Epstein-Barr virus (EBV) infection. Studies have reported familial aggregation of NPC, but evidence has been mixed for elevated rates of cancers other than NPC. METHODS: The authors reassessed their previous evaluation of familial aggregation of cancer in 348 high-risk Taiwanese multiplex families with 2 or more NPC cases enrolled between 1980 and 2003...
July 29, 2021: Cancer
https://read.qxmd.com/read/34324486/body-size-and-composition-and-risk-of-site-specific-cancers-in-the-uk-biobank-and-large-international-consortia-a-mendelian-randomisation-study
#7
Mathew Vithayathil, Paul Carter, Siddhartha Kar, Amy M Mason, Stephen Burgess, Susanna C Larsson
BACKGROUND: Evidence for the impact of body size and composition on cancer risk is limited. This mendelian randomisation (MR) study investigates evidence supporting causal relationships of body mass index (BMI), fat mass index (FMI), fat-free mass index (FFMI), and height with cancer risk. METHODS AND FINDINGS: Single nucleotide polymorphisms (SNPs) were used as instrumental variables for BMI (312 SNPs), FMI (577 SNPs), FFMI (577 SNPs), and height (293 SNPs). Associations of the genetic variants with 22 site-specific cancers and overall cancer were estimated in 367,561 individuals from the UK Biobank (UKBB) and with lung, breast, ovarian, uterine, and prostate cancer in large international consortia...
July 2021: PLoS Medicine
https://read.qxmd.com/read/34324483/mexican-consensus-on-hodgkin-s-lymphoma
#8
José L Álvarez-Vera, Jocelyn Aguilar-Luevano, Luisa M Alcívar-Cedeño, Luara L Arana-Luna, Luis Arteaga-Ortiz, Pamela E Báez-Islas, Ana Carolina-Reynoso, Gabriela Cesarman-Maus, José A De la Peña-Celaya, María E Espitia-Ríos, Denisse J Fermín-Caminero, Willy Flores-Patricio, Alinka S García-Camacho, Pedro G Guzmán-Mora, Ana K Hernández-Colín, Eleazar Hernández-Ruiz, Wilfrido Herrera-Olivares, Elvia Jacobo-Medrano, Sergio J Loera-Fragoso, Juan P Macías-Flores, Mario A Martínez-Ramírez, Liliana Medina-Guzmán, Andrea I Milán-Salvatierra, Leire Montoya-Jiménez, Javier de J Morales-Adrián, Aldo Mujica-Martínez, Lorena Nava-Villegas, Juan J Orellana-Garibay, Orlando G Palma-Moreno, Juan M Pérez-Zúñiga, Karen D Pérez-Gómez, Yayra M Pichardo-Cepín, Flavio Rojas-Castillejos, Eduardo Romero-Martínez, Hilda Romero-Rodelo, Adela Segura-García, Karina Silva-Vera, Ana L Tapía-Enríquez, Óscar Teomitzi-Sánchez, Fredy Tepepa-Flores, Shendel P Vilchis-González, Atenas Villela-Peña, Lidia V Guerra-Alarcón, Rodrigo Reséndiz-Olea, Luisa Banda-García, Eugenia P Paredes-Lozano, Martha Alvarado-Ibarra
El linfoma de Hodgkin (LH) se debe a la transformación clonal de células originadas en los linfocitos B, lo que genera las células binucleadas patognomónicas de Reed-Sternberg. El LH es una enfermedad de células B con una distribución bimodal, con mayor incidencia en la adolescencia y la tercera década de la vida y un segundo pico en personas mayores de 55 años. Las células del LH clásico habitualmente sufren una reprogramación de la expresión génica, ya que pierden la expresión de la mayoría de los genes típicos de las células B y han adquirido la expresión de múltiples genes que son típicos de otros tipos de células del sistema inmunitario...
2021: Gaceta Médica de México
https://read.qxmd.com/read/34324434/curcumin-in-combination-with-homoharringtonine-suppresses-lymphoma-cell-growth-by-inhibiting-the-tgf-%C3%AE-smad3-signaling-pathway
#9
Yu Zhang, Jingjing Xiang, Ni Zhu, Hangping Ge, Xianfu Sheng, Shu Deng, Junfa Chen, Lihong Yu, Yan Zhou, Jianping Shen
Both homoharringtonine (HHT) and curcumin exhibit anti-proliferative effects on lymphoma cells, but the effects of combined HHT and curcumin treatment remain unclear. Here, we investigated the effects of HHT/curcumin combination on the proliferation, apoptosis, and invasion in lymphoma cells. CCK-8, flow cytometry, and transwell assays were used to assess proliferation, apoptosis, and invasion of U937 and Raji cells. p-Smad3, E-cadherin, and N-cadherin expression were also measured in Raji cells using Western blot assays...
July 29, 2021: Aging
https://read.qxmd.com/read/34324220/multi-center-analysis-of-practice-patterns-and-outcomes-of-younger-and-older-patients-with-mantle-cell-lymphoma-in-the-rituximab-era
#10
Reem Karmali, Jeffrey M Switchenko, Subir Goyal, Krithika Shanmugasundaram, Michael C Churnetski, Bhaskar Kolla, Veronika Bachanova, James N Gerson, Stefan K Barta, Max J Gordon, Alexey V Danilov, Natalie S Grover, Narendranath Epperla, Stephanie Mathews, Madelyn Burkart, Yazeed Sawalha, Brian T Hill, Nilanjan Ghosh, Steven I Park, David A Bond, Kami J Maddocks, Talha Badar, Timothy S Fenske, Mehdi Hamadani, Jin Guo, Mary Malecek, Brad S Kahl, Peter Martin, Kristie A Blum, Christopher R Flowers, Jonathon B Cohen
Clinical outcomes and predictors of survival in patients with newly diagnosed mantle cell lymphoma (MCL) treated in the rituximab era (2000-2015) at 12 US academic centers were assessed to identify determinants of survival across age groups. Objectives were to characterize and compare practice patterns, outcomes and prognostic factors for survival in younger pts (age < 65) and older pts (age ≥ 65 yrs). Among 1162 patients included, 697 were younger and 465 were older. In younger patients, 2-year progression free survival (PFS) and overall survival (OS) rates were 79% and 92% respectively; blastoid histology, ECOG ≥2, and lack of maintenance rituximab (MR) remained statistically relevant to poor OS on univariate analysis (UVA) and multivariate analysis (MVA)...
July 29, 2021: American Journal of Hematology
https://read.qxmd.com/read/34324199/heterogeneity-of-germinal-center-b-cells-new-insights-from-single-cell-studies
#11
REVIEW
Noudjoud Attaf, Sabrina Baaklini, Laurine Binet, Pierre Milpied
Upon antigen exposure, activated B cells in antigen-draining lymphoid organs form micro-anatomical structures, called germinal centers (GCs), where affinity maturation occurs. Within the GC microenvironment, GC B cells undergo proliferation and B cell receptor (BCR) genes somatic hypermutation in the dark zone (DZ), and affinity-based selection in the light zone (LZ). In the current paradigm of GC dynamics, high affinity LZ B cells may be selected by cognate T follicular helper cells to either differentiate into plasma cells or memory B cells, or re-enter the DZ and initiate a new round of proliferation and BCR diversification, before migrating back to the LZ...
July 29, 2021: European Journal of Immunology
https://read.qxmd.com/read/34323958/prognostic-significance-of-fcgr2b-expression-for-the-response-of-dlbcl-patients-to-rituximab-or-obinutuzumab-treatment
#12
Malgorzata Nowicka, Laura K Hilton, Margaret Ashton-Key, Chantal E Hargreaves, Chern Lee, Russell Foxall, Matthew J Carter, Stephen A Beers, Kathleen N Potter, Christopher R Bolen, Christian Klein, Andrea Knapp, Farheen Mir, Matthew Rose-Zerilli, Cathy Burton, Wolfram Klapper, David W Scott, Laurie H Sehn, Umberto Vitolo, Maurizio Martelli, Marek Trneny, Christopher K Rushton, Graham W Slack, Pedro Farinha, Jonathan C Strefford, Mikkel Z Oestergaard, Ryan D Morin, Mark S Cragg
Fc γ receptor IIB (FcγRIIB) is an inhibitory molecule capable of reducing antibody immunotherapy efficacy. We hypothesized its expression could confer resistance in patients with diffuse large B-cell lymphoma (DLBCL) treated with anti-CD20 monoclonal antibody (mAb) chemoimmunotherapy, with outcomes varying depending on mAb (rituximab [R]/obinutuzumab [G]) because of different mechanisms of action. We evaluated correlates between FCGR2B messenger RNA and/or FcγRIIB protein expression and outcomes in 3 de novo DLBCL discovery cohorts treated with R plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reported by Arthur, Schmitz, and Reddy, and R-CHOP/G-CHOP-treated patients in the GOYA trial (NCT01287741)...
August 10, 2021: Blood Advances
https://read.qxmd.com/read/34323957/single-nucleotide-fc%C3%AE-receptor-polymorphisms-do-not-impact-obinutuzumab-rituximab-outcome-in-patients-with-lymphoma
#13
Jonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, Cathy Burton, Andrew Davies, Rosalind Ganderton, Wolfgang Hiddemann, Chisako Iriyama, Wolfram Klapper, Kate V Latham, Maurizio Martelli, Farheen Mir, Helen Parker, Kathleen N Potter, Matthew J J Rose-Zerilli, Laurie H Sehn, Marek Trněný, Umberto Vitolo, Christopher R Bolen, Christian Klein, Andrea Knapp, Mikkel Z Oestergaard, Mark S Cragg
Single-nucleotide polymorphisms (SNPs) have been shown to influence Fcγ receptor (FcγR) affinity and activity, but their effect on treatment response is unclear. We assessed their importance in the efficacy of obinutuzumab or rituximab combined with chemotherapy in untreated advanced follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the GALLIUM (www.clinicaltrials.gov #NCT01332968) and GOYA (#NCT01287741) trials, respectively. Genomic DNA was extracted from patients enrolled in GALLIUM (n = 1202) and GOYA (n = 1418)...
August 10, 2021: Blood Advances
https://read.qxmd.com/read/34323643/effectiveness-of-brentuximab-vedotin-monotherapy-in-relapsed-or-refractory-hodgkin-lymphoma-a-systematic-review-and-meta-analysis
#14
Wouter J Plattel, Aurore Bergamasco, Fabrizio Trinchese, François Gavini, Nawal Bent-Ennakhil, Athanasios Zomas, Genaro Castillon, Teigna Arredondo-Bisono, Tiffany Cristarella, Yola Moride, Bastian von Tresckow
This systematic review and meta-analysis aimed to determine the effectiveness of brentuximab vedotin (BV) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) in the clinical practice setting using most recent results. A total of 32 observational studies reporting on treatment patterns, overall response rate (ORR), complete response (CR) rate, progression-free survival (PFS), overall survival (OS), and adverse events were found. After four cycles, a random-effect model yielded pooled ORR and CR rates of 62...
July 29, 2021: Leukemia & Lymphoma
https://read.qxmd.com/read/34323164/a-2-1-randomized-open-label-phase-ii-study-of-selinexor-vs-physician-s-choice-in-older-patients-with-relapsed-or-refractory-acute-myeloid-leukemia
#15
Kendra Sweet, Bhavana Bhatnagar, Hartmut Döhner, Will Donnellan, Olga Frankfurt, Michael Heuser, Vamsi Kota, Hongtao Liu, Emmanuel Raffoux, Gail J Roboz, Christoph Röllig, Margaret M Showel, Stephen A Strickland, Susana Vives, Shijie Tang, Thaddeus J Unger, Anita Joshi, Yao Shen, Mariano J Alvarez, Andrea Califano, Marsha Crochiere, Yosef Landesman, Michael Kauffman, Jatin Shah, Sharon Shacham, Michael R Savona, Pau Montesinos
Selinexor, a selective inhibitor of nuclear export, has demonstrated promising activity in patients with acute myeloid leukemia (AML). This randomized, phase II study evaluated selinexor 60 mg twice weekly ( n  = 118) vs. physician's choice (PC) treatment ( n  = 57) in patients aged ≥60 years with relapsed/refractory (R/R) AML. The primary outcome was overall survival (OS). Median OS did not differ significantly for selinexor vs. PC (3.2 vs. 5.6 months; HR = 1.18 [95% CI: 0.79-1.75]; p  = 0...
July 29, 2021: Leukemia & Lymphoma
https://read.qxmd.com/read/34323157/role-of-quantitative-hepatitis-b-surface-antibodies-in-preventing-hepatitis-b-virus-related-hepatitis-in-patients-treated-with-rituximab
#16
Sung-Nan Pei, Yan-Fang Liu, Chin-Yuan Kuo, Ming-Chung Wang, Ming-Chun Ma, Chun-Kai Liao, Hwee-Yeong Ng, Chien-Hung Chen
Hepatitis B virus (HBV) reactivation is a well-known complication after rituximab-based chemotherapy in patients with B cell lymphoma (BCL) who have resolved HBV infection. This retrospective cohort study used electronic medical records from the Kaohsiung Chang Gung Memorial Hospital. There were 128 patients with BCL and resolved HBV infection treated with 1st-line rituximab-containing therapy from 2008 to 2013. No patient received antiviral prophylaxis. Patients with high pretreatment hepatitis B surface antibody (anti-HBs titer ≥100 mIU/mL), had significantly less HBV reactivation (2...
July 29, 2021: Leukemia & Lymphoma
https://read.qxmd.com/read/34323129/a-cost-effectiveness-analysis-of-front-line-treatment-strategies-in-early-stage-follicular-lymphoma
#17
Joshua W D Tobin, Anna Crothers, Ti Eric Ma, Peter Mollee, Maher K Gandhi, Paul Scuffham, Greg Hapgood
Recent data suggest the use of radiotherapy alone (RT) in Early-Stage Follicular Lymphoma is declining. Cost-effectiveness analysis of treatments has not been performed. We constructed a partitioning model (15-year horizon) to compare RT, combined-modality therapy (CMT) and immunochemotherapy with rituximab maintenance (ICT + RM) from a PET-staged cohort from the Australian Lymphoma Alliance. Lifetime direct health care costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were calculated...
July 29, 2021: Leukemia & Lymphoma
https://read.qxmd.com/read/34322289/nivolumab-in-relapsed-refractory-hodgkin-lymphoma-towards-a-new-treatment-strategy
#18
Emanuele Cencini, Monica Bocchia, Alberto Fabbri
Chemo-refractory Hodgkin lymphoma (HL), especially after failure of high-dose therapy and autologous stem cell transplantation (ASCT), has a very poor prognosis. Nivolumab, an anti-PD-1 monoclonal antibody, demonstrated durable responses and manageable toxicity in a significant proportion of HL patients who fail both ASCT and brentuximab vedotin. Although anti-PD-1 treatment is often well tolerated, immune-related adverse events (iAE) were frequently observed. New perspectives could be represented by treatment discontinuation in patients with prolonged response or toxicity with the possibility of a re-treatment at relapse, subsequent chemotherapy or a modification of the dose-intensity or treatment duration...
2021: American Journal of Blood Research
https://read.qxmd.com/read/34322285/the-non-leukemic-t-cell-large-granular-lymphocytic-leukemia-variant-with-marked-splenomegaly-and-neutropenia-in-the-setting-of-rheumatoid-arthritis-felty-syndrome-and-hepatosplenic-t-cell-lymphoma-mask
#19
Vadim Gorodetskiy, Natalya Probatova, Yulia Sidorova, Natalia Kupryshina, Tatiana Obukhova, Vladimir Vasilyev, Natalya Ryzhikova, Andrey Sudarikov
T cell large granular lymphocytic (T-LGL) leukemia is a rare type of mature T cell neoplasm. The typical features of T-LGL leukemia include an increased number of large granular lymphocytes in the peripheral blood, cytopenia (most commonly neutropenia), and mild-to-moderate splenomegaly. Up to 28% of patients with T-LGL leukemia have rheumatoid arthritis (RA). This study reports ten atypical cases (seven women and three men, median age 60.5 years) of RA-associated T-LGL leukemia presenting with lymphopenia, severe neutropenia, and marked splenomegaly...
2021: American Journal of Blood Research
https://read.qxmd.com/read/34322250/primary-follicular-lymphoma-of-colon-a-case-series-and-review-of-literature
#20
Abdul Mohammed, Farnaz Shariati, Neethi Paranji, Nisheet Waghray
Follicular lymphoma of the colon is rare, accounting for 1% to 2% of cases in the gastrointestinal tract. Despite the absence of randomized clinical trials, NCCN stage III and IV colonic follicular lymphomas are routinely treated with chemotherapy with good clinical response. We present 2 cases of advanced stage follicular lymphoma of colon that were effectively treated with bendamustine-based chemotherapy regimens.
July 2021: Clinical Case Reports
keyword
keyword
958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"